Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus TENATHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus TENATHAN.
LODINE vs TENATHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
TENATHAN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin levels in the synaptic cleft.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
1 tablet (40 mg) orally once daily, increased to 80 mg once daily if needed after 4 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Terminal elimination half-life is 4-6 hours; in severe renal impairment (CrCl <30 mL/min) may extend to 8-12 hours, requiring dose adjustment.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Category C
Category C
NSAID
NSAID